Partners in the COVID-19 Therapeutics Accelerator on Tuesday announced grants of USD20 million (Sh2 billion) to three institutions—the University of Washington, University of Oxford, and La Jolla Institute for Immunology—to fund clinical trials in order to identify highly potent immunotherapies for the COVID-19 pandemic.
These grants mark the first investments to come from the COVID-19 Therapeutics Accelerator, a large-scale initiative launched by the Bill and Melinda Gates Foundation, Wellcome, and Mastercard to speed the development of and access to therapies for COVID-19.